Nebius Customer AtlasNot affiliated · Research by Not affiliated · By @anthonybs
Not affiliated with Nebius · Independent research by @anthonybsSee changes
AllConverge Bio

Converge Bio

AI tools for biological research

How they use Nebius

Converge Bio trained Converge-SC on Nebius infrastructure using more than 36 million single cells and approximately 2TB of transcriptomic data. Nebius says training required 7,000 NVIDIA H100 GPU hours accessed through distributed clusters, NVIDIA CUDA and Nebius AI Studio. Its healthcare solutions page specifies H100 80GB GPUs.

The model reads gene-expression patterns for biological research and drug discovery. It processes more than 20,000 genes per cell using a 30K context length, preserves raw numerical expression values and supports patient-level analysis. Nebius says Converge-SC was built for interpretability and usability, with a goal of delivering explainable, patient-specific insights for drug discovery and precision medicine. Nebius reports that Converge-SC outperformed baseline models on disease classification and drug perturbation tasks. Nebius also says the model was released via Hugging Face. Oded Kalev also described building the single-cell model on Nebius’s AI platform. In a BioPharma APAC interview, Nebius’s Ilya Burkov said Converge Bio used its AI platform to analyze 36 million single cells in days rather than months.

Converge Bio’s co-founder identified Nebius on-demand GPUs as part of the company’s ML-first research stack built during 2024–2025. He described the GPUs as providing elasticity while the team developed production-grade biological model pipelines.

Sources

6 sources

Cloud for Scientific AI and Healthcare

19 Oct 2026 · nebius.com · Web page

Nebius features Converge Bio’s Converge-SC training as a customer case using over 36 million cells, 2TB of data and H100 80GB GPUs with advanced parallelism. The model was built for interpretability and usability, with a goal of delivering explainable, patient-specific insights for drug discovery and precision medicine. Nebius reports improved disease classification and drug perturbation results over baseline models and release via Hugging Face.

Open original source
Cloud for Scientific AI and Healthcare19 Oct 2026 · nebius.com · Web pageNebius features Converge Bio’s Converge-SC training as a customer case using over 36 million cells, 2TB of data and H100 80GB GPUs with advanced parallelism. The model was built for interpretability and usability, with a goal of delivering explainable, patient-specific insights for drug discovery and precision medicine. Nebius reports improved disease classification and drug perturbation results over baseline models and release via Hugging Face.

Oded Kalev on Converge Bio's research stack

26 Nov 2025 · LinkedIn · Web page

Oded Kalev identifies Nebius on-demand GPUs as part of Converge Bio’s ML-first research stack built during 2024–2025, providing elasticity for biological model pipelines.

Open original source
Oded Kalev on Converge Bio's research stack26 Nov 2025 · LinkedIn · Web pageOded Kalev identifies Nebius on-demand GPUs as part of Converge Bio’s ML-first research stack built during 2024–2025, providing elasticity for biological model pipelines.

Nebius Is Accelerating Drug Discovery with AI Infrastructure That Slashes Timelines from Years to Months

4 Aug 2025 · www.biopharmaapac.com · Web page

Ilya Burkov says Converge Bio used Nebius’s AI platform to analyze 36 million single cells in days rather than months to understand cellular disease mechanisms.

Open original source
Nebius Is Accelerating Drug Discovery with AI Infrastructure That Slashes Timelines from Years to Months4 Aug 2025 · www.biopharmaapac.com · Web pageIlya Burkov says Converge Bio used Nebius’s AI platform to analyze 36 million single cells in days rather than months to understand cellular disease mechanisms.

Nebius support testimonial

29 Sept 2026 · Nebius · Web page

Noam Azoulay, an ML engineer at Converge Bio, says Nebius’s responsive support addressed the team’s challenges and supported its research.

Open original source
Nebius support testimonial29 Sept 2026 · Nebius · Web pageNoam Azoulay, an ML engineer at Converge Bio, says Nebius’s responsive support addressed the team’s challenges and supported its research.

Nebius Customer story

14 May 2025 · Nebius · Web page

Customer story: develops biology AI with Nebius GPU infrastructure.

Open original source
Nebius Customer story14 May 2025 · Nebius · Web pageCustomer story: develops biology AI with Nebius GPU infrastructure.

Company context

converge-bio.com

Converge Bio develops generative AI software for biotechnology and pharmaceutical researchers working on drug discovery and development. Its models analyze DNA, RNA and protein sequences to support antibody engineering, target and biomarker discovery, and protein manufacturing. Its products include ConvergeAB for designing and optimizing antibodies, ConvergeGEO for optimizing gene expression and protein yields, and ConvergeCELL for generating therapeutic hypotheses from transcriptomics data. Scientists use these tools to prioritize biological targets and design sequences for experimental testing.

Converge Bio

Documented financing · private company

Amount$25MSeries A
· Converge Bio press release

Recent updates

1 update
  1. Funding

    Converge Bio raises $25 million Series A

    Converge Bio announced $25 million in Series A funding, bringing its reported total raised to $30 million.

    Converge Bio PR Newswire release
Next, A–ZCore Automation
← Explore all customers

Converge Bio

Biology AI tools · Health

How they use Nebius

Converge Bio trained Converge-SC on Nebius infrastructure using more than 36 million single cells and approximately 2TB of transcriptomic data. Nebius says training required 7,000 NVIDIA H100 GPU hours accessed through distributed clusters, NVIDIA CUDA and Nebius AI Studio. Its healthcare solutions page specifies H100 80GB GPUs.

The model reads gene-expression patterns for biological research and drug discovery. It processes more than 20,000 genes per cell using a 30K context length, preserves raw numerical expression values and supports patient-level analysis. Nebius says Converge-SC was built for interpretability and usability, with a goal of delivering explainable, patient-specific insights for drug discovery and precision medicine. Nebius reports that Converge-SC outperformed baseline models on disease classification and drug perturbation tasks. Nebius also says the model was released via Hugging Face. Oded Kalev also described building the single-cell model on Nebius’s AI platform. In a BioPharma APAC interview, Nebius’s Ilya Burkov said Converge Bio used its AI platform to analyze 36 million single cells in days rather than months.

Converge Bio’s co-founder identified Nebius on-demand GPUs as part of the company’s ML-first research stack built during 2024–2025. He described the GPUs as providing elasticity while the team developed production-grade biological model pipelines.

Sources

6 sources

Cloud for Scientific AI and Healthcare

19 Oct 2026 · nebius.com · Web page

Nebius features Converge Bio’s Converge-SC training as a customer case using over 36 million cells, 2TB of data and H100 80GB GPUs with advanced parallelism. The model was built for interpretability and usability, with a goal of delivering explainable, patient-specific insights for drug discovery and precision medicine. Nebius reports improved disease classification and drug perturbation results over baseline models and release via Hugging Face.

Open original source
Cloud for Scientific AI and Healthcare19 Oct 2026 · nebius.com · Web pageNebius features Converge Bio’s Converge-SC training as a customer case using over 36 million cells, 2TB of data and H100 80GB GPUs with advanced parallelism. The model was built for interpretability and usability, with a goal of delivering explainable, patient-specific insights for drug discovery and precision medicine. Nebius reports improved disease classification and drug perturbation results over baseline models and release via Hugging Face.

Oded Kalev on Converge Bio's research stack

26 Nov 2025 · LinkedIn · Web page

Oded Kalev identifies Nebius on-demand GPUs as part of Converge Bio’s ML-first research stack built during 2024–2025, providing elasticity for biological model pipelines.

Open original source
Oded Kalev on Converge Bio's research stack26 Nov 2025 · LinkedIn · Web pageOded Kalev identifies Nebius on-demand GPUs as part of Converge Bio’s ML-first research stack built during 2024–2025, providing elasticity for biological model pipelines.

Nebius Is Accelerating Drug Discovery with AI Infrastructure That Slashes Timelines from Years to Months

4 Aug 2025 · www.biopharmaapac.com · Web page

Ilya Burkov says Converge Bio used Nebius’s AI platform to analyze 36 million single cells in days rather than months to understand cellular disease mechanisms.

Open original source
Nebius Is Accelerating Drug Discovery with AI Infrastructure That Slashes Timelines from Years to Months4 Aug 2025 · www.biopharmaapac.com · Web pageIlya Burkov says Converge Bio used Nebius’s AI platform to analyze 36 million single cells in days rather than months to understand cellular disease mechanisms.

Nebius support testimonial

29 Sept 2026 · Nebius · Web page

Noam Azoulay, an ML engineer at Converge Bio, says Nebius’s responsive support addressed the team’s challenges and supported its research.

Open original source
Nebius support testimonial29 Sept 2026 · Nebius · Web pageNoam Azoulay, an ML engineer at Converge Bio, says Nebius’s responsive support addressed the team’s challenges and supported its research.

Nebius Customer story

14 May 2025 · Nebius · Web page

Customer story: develops biology AI with Nebius GPU infrastructure.

Open original source
Nebius Customer story14 May 2025 · Nebius · Web pageCustomer story: develops biology AI with Nebius GPU infrastructure.

Company context

converge-bio.com

Converge Bio develops generative AI software for biotechnology and pharmaceutical researchers working on drug discovery and development. Its models analyze DNA, RNA and protein sequences to support antibody engineering, target and biomarker discovery, and protein manufacturing. Its products include ConvergeAB for designing and optimizing antibodies, ConvergeGEO for optimizing gene expression and protein yields, and ConvergeCELL for generating therapeutic hypotheses from transcriptomics data. Scientists use these tools to prioritize biological targets and design sequences for experimental testing.

Converge Bio

Documented financing · private company

Amount$25MSeries A
· Converge Bio press release

Recent updates

1 update
  1. Funding

    Converge Bio raises $25 million Series A

    Converge Bio announced $25 million in Series A funding, bringing its reported total raised to $30 million.

    Converge Bio PR Newswire release